The main functions and mechanism of action of tofacitinib tablets

Tofacitinib (Tofacitinib) is an oral small molecule drug that belongs to the Janus kinase (JAK) inhibitor class and is specifically designed to interfere with abnormal activity of the immune system. Its main function is to reduce the chronic inflammatory response by selectively inhibiting JAK1 and JAK3 and blocking the signaling of multiple pro-inflammatory cytokines. Under normal circumstances, after cell surface receptors bind to cytokines, gene transcription is initiated through the JAK-STAT pathway, activating immune cells to trigger inflammation. By inhibiting this pathway, tofacitinib effectively reduces the activity of cytokines such as IL-6, IL-2, IL-15, IFN-γ, etc., inhibits the excessive activation of T cells and B cells, and thereby controls the pathological process of immune-related diseases.

Clinically, tofacitinib has been approved for the treatment of moderately to severely active rheumatoid arthritis (RA), psoriatic arthritis (PsA) and moderate to severe ulcerative colitis (UC). In rheumatoid arthritis, tofacitinib can significantly improve joint swelling and tenderness, and delay the process of bone and joint destruction; and combination with methotrexate is recognized as a strategy that can both enhance efficacy and is relatively safe and controllable, and is especially suitable for patients with moderate to severe active rheumatoid arthritis; in ulcerative colitis, it helps promote mucosal healing and relieves symptoms of diarrhea and bloody stools. Compared with traditional immunosuppressants, tofacitinib has a faster onset of action, convenient dosage form, and higher patient compliance.

However, because it suppresses a wide range of immune responses, it also brings potential risks such as infection, elevated blood lipids, and cardiovascular events. Therefore, in practical applications, it is necessary to strictly screen patients' underlying diseases and regularly monitor the safety of treatment. With the accumulation of more real-world data, the positioning and application strategies of tofacitinib in different immune disease fields are constantly being refined and improved.

Reference materials:https://www.xeljanz.com/